Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening

Abstract

Traditional high-throughput drug screening in oncology routinely relies on two-dimensional (2D) cell models, which inadequately recapitulate the physiologic context of cancer. Three-dimensional (3D) cell models are thought to better mimic the complexity of in vivo tumors. Numerous methods to culture 3D organoids have been described, but most are nonhomogeneous and expensive, and hence impractical for high-throughput screening (HTS) purposes. Here we describe an HTS-compatible method that enables the consistent production of organoids in standard flat-bottom 384- and 1536-well plates by combining the use of a cell-repellent surface with a bioprinting technology incorporating magnetic force. We validated this homogeneous process by evaluating the effects of well-characterized anticancer agents against four patient-derived pancreatic cancer KRAS mutant-associated primary cells, including cancer-associated fibroblasts. This technology was tested for its compatibility with HTS automation by completing a cytotoxicity pilot screen of ~3300 approved drugs. To highlight the benefits of the 3D format, we performed this pilot screen in parallel in both the 2D and 3D assays. These data indicate that this technique can be readily applied to support large-scale drug screening relying on clinically relevant, ex vivo 3D tumor models directly harvested from patients, an important milestone toward personalized medicine.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 43

1. 1.
   3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained · 2016

   No notice
2. 2.

   Powell K. Adding Depth to Cell Culture. Science 2017, 356 (6333), 96–98.

   Not in our library

3. 3.

   Clevers H. Modeling Development and Disease with Organoids. Cell 2016, 165 (7), 1586–1597.

   Not in our library10.1016/j.cell.2016.05.082

4. 4.

   Madoux F. Tanner A. Vessels M. et al A 1536-Well 3D Viability Assay to Assess the Cytotoxic Effect of Drugs on Spheroids. SLAS Discov. 2017, 22 (5), 516–524.

   Not in our library10.1177/2472555216686308

5. 5.

   Zhang J.-H. Chung T. D. Y. Oldenburg K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4 (2), 67–73.

   Not in our library10.1177/108705719900400206

6. 6.
   3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing · 2013

   No notice
7. 7.

   Hruban R. H. Goggins M. Parsons J. et al Progression Model for Pancreatic Cancer. Clin. Cancer Res. 2000, 6 (8), 2969–2972.

   Not in our library

8. 8.

   Boehnke K. Iversen P. W. Schumacher D. et al Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. J. Biomol. Screen. 2016, 21 (9), 931–941.

   Not in our library10.1177/1087057116650965

9. 9.

   Lin R.-Z. Chang H.-Y. Recent Advances in Three-Dimensional Multicellular Spheroid Culture for Biomedical Research. Biotechnol. J. 2008, 3 (9–10), 1172–1184.

   Not in our library10.1002/biot.200700228

10. 10.

    Costa E. C. Moreira A. F. de Melo-Diogo D. et al 3D Tumor Spheroids: An Overview on the Tools and Techniques Used for Their Analysis. Biotechnol. Adv. 2016, 34 (8), 1427–1441.

    Not in our library10.1016/j.biotechadv.2016.11.002

11. 11.

    Biankin A. V. Waddell N. Kassahn K. S. et al Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes. Nature 2012, 491 (7424), 399–405.

    Not in our library10.1038/nature11547

12. 12.

    Baker L. A. Tiriac H. Clevers H. et al Modeling Pancreatic Cancer with Organoids. Trends Cancer 2016, 2 (4), 176–190.

    Not in our library10.1016/j.trecan.2016.03.004

13. 13.

    Boj S. F. Hwang C.-I. Baker L. A. et al Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell 2015, 160 (1), 324–338.

    Not in our library10.1016/j.cell.2014.12.021

14. 14.

    Jaffee E. M. Hruban R. H. Canto M. et al Focus on Pancreas Cancer. Cancer Cell 2002, 2 (1), 25–28.

    Not in our library10.1016/s1535-6108(02)00093-4

15. 15.

    Siegel R. L. Miller K. D. Jemal A. Cancer Statistics, 2015. CA Cancer J. Clin. 2015, 65 (1), 5–29.

    Not in our library10.3322/caac.21254

16. 16.

    Rasheed Z. A. Matsui W. Maitra A. Pancreatic Cancer and Tumor Microenvironment. In Pancreatic Cancer and Tumor Microenvironment; Grippo P. J. Hidayatullah H. G., Eds.; Trivandrum:Kerala, India, 2012; chap. 1.

    Not in our library

17. 17.

    Öhlund D. Elyada E. Tuveson D. Fibroblast Heterogeneity in the Cancer Wound. J. Exp. Med. 2014, 211 (8), 1503–1523.

    Not in our library10.1084/jem.20140692

18. 18.

    Karagiannis G. S. Poutahidis T. Erdman S. E. et al Cancer-Associated Fibroblasts Drive the Progression of Metastasis through both Paracrine and Mechanical Pressure on Cancer Tissue. Mol. Cancer Res. 2012, 10 (11), 1403–1418.

    Not in our library10.1158/1541-7786.mcr-12-0307

19. 19.

    Feig C. Gopinathan A. Neesse A. et al The Pancreas Cancer Microenvironment. Clin. Cancer Res. 2012, 18 (16), 4266–4276.

    Not in our library10.1158/1078-0432.ccr-11-3114

20. 20.

    Tseng H. Gage J. A. Shen T. et al A Spheroid Toxicity Assay Using Magnetic 3D Bioprinting and Real-Time Mobile Device-Based Imaging. Sci. Rep. 2015, 5, 13987.

    Not in our library10.1038/srep13987

21. 21.

    Hou S. Madoux F. Scampavia L. et al Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease. SLAS Discov. 2017, 22 (7), 887–896.

    Not in our library10.1177/2472555217689992

22. 22.

    Pedro-Rosa L. Buckner F. S. Ranade R. M. et al Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNA Synthetase via High-Throughput Orthogonal Screening. J. Biomol. Screen. 2015, 20 (1), 122–130.

    Not in our library10.1177/1087057114548832

23. 23.

    Smith E. Chase P. Niswender C. M. et al Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). J. Biomol. Screen. 2015, 20 (7), 858–868.

    Not in our library10.1177/1087057115581770

24. 24.

    Madoux F. Dreymuller D. Pettiloud J.-P. et al Discovery of an Enzyme and Substrate Selective Inhibitor of ADAM10 Using an Exosite-Binding Glycosylated Substrate. Sci. Rep. 2016, 6 (1), 11.

    Not in our library10.1038/s41598-016-0013-4

25. 25.

    Collia D. Bannister T. D. Tan H. et al A Rapid Phenotypic Whole-Cell Screening Approach for the Identification of Small-Molecule Inhibitors That Counter β-Lactamase Resistance in Pseudomonas aeruginosa. SLAS Discov. 2018, 23 (1), 55–64.

    Not in our library10.1177/2472555217728489

26. 26.

    Friedrich J. Seidel C. Ebner R. et al Spheroid-Based Drug Screen: Considerations and Practical Approach. Nat. Protoc. 2009, 4 (3), 309–324.

    Not in our library10.1038/nprot.2008.226

27. 27.

    Lin R.-Z. Chou L.-F. Chien C.-C. M. et al Dynamic Analysis of Hepatoma Spheroid Formation: Roles of E-Cadherin and β1-Integrin. Cell Tissue Res. 2006, 324 (3), 411–422.

    Not in our library10.1007/s00441-005-0148-2

28. 28.

    Ivascu A. Kubbies M. Diversity of Cell-Mediated Adhesions in Breast Cancer Spheroids. Int. J. Oncol. 2007, 31 (6), 1403–1413.

    Not in our library

29. 29.

    Wolff R. E. A. Dynamic Changes during the Treatment of Pancreatic Cancer. Oncotarget 2018, 1–27.

    Not in our library10.18632/oncotarget.24483

30. 30.

    Baillargeon P. Scampavia L. Einsteder R. et al Monitoring of HTS Compound Library Quality via a High-Resolution Image Acquisition and Processing Instrument. J. Lab. Autom. 2011, 16 (3), 197–203.

    Not in our library10.1016/j.jala.2011.02.004

31. 31.

    Shelper T. B. Lovitt C. J. Avery V. M. Assessing Drug Efficacy in a Miniaturized Pancreatic Cancer In Vitro 3D Cell Culture Model. Assay Drug Dev. Technol. 2016, 14 (7), 367–380.

    Not in our library10.1089/adt.2016.737

32. 32.

    Mathews Griner L. A. Zhang X. Guha R. et al Large-Scale Pharmacological Profiling of 3D Tumor Models of Cancer Cells. Cell Death Dis. 2016, 7 (12), e2492.

    Not in our library10.1038/cddis.2016.360

33. 33.
    Integrin Signaling in Cancer Cell Survival and Chemoresistance · 2012

    No notice
34. 34.

    Neesse A. Krug S. Gress T. M. et al Emerging Concepts in Pancreatic Cancer Medicine: Targeting the Tumor Stroma. Onco Targets Ther. 2013, 7, 33–43.

    Not in our library10.2147/ott.s38111

35. 35.

    Chen D. Cui Q. C. Yang H. et al Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome Activity. Cancer Res. 2006, 66 (21), 10425–10433.

    Not in our library10.1158/0008-5472.can-06-2126

36. 36.

    Alberts B. Johnson A. Lewis J. et al Molecular Biology of the Cell; Garland Science: New York, 2002; 4th ed.

    Not in our library

37. 37.

    Gervasoni J. E. Hindenburg A. A. Vezeridis M. P. et al An Effective In Vitro Antitumor Response against Human Pancreatic Carcinoma with Paclitaxel and Daunorubicin by Induction of Both Necrosis and Apoptosis. Anticancer Res. 2004, 24 (5A), 2617–2626.

    Not in our library

38. 38.

    Lövborg H. Öberg F. Rickardson L. et al Inhibition of Proteasome Activity, Nuclear Factor-KB Translocation and Cell Survival by the Antialcoholism Drug Disulfiram. Int. J. Cancer 2006, 118 (6), 1577–1580.

    Not in our library10.1002/ijc.21534

39. 39.

    Skrott Z. Mistrik M. Andersen K. K. et al Alcohol-Abuse Drug Disulfiram Targets Cancer via p97 Segregase Adaptor NPL4. Nature 2017, 552 (7684), 194–199.

    Not in our library10.1038/nature25016

40. 40.

    ClinicalTrials.gov. Disulfiram and Gemcitabine Hydrochloride in Treating Patients with Unresectable Solid Tumors or Metastatic Pancreatic Cancer. U.S. National Library of Medicine Feb 2016, NCT02671890. https://clinicaltrials.gov/show/NCT02671890.

    Not in our library

Cited by papers we hold 1

• 3D Bioprinted cancer models: Revolutionizing personalized cancer therapy · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.